

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (currently amended) A method for managing batches of immunocompetent cells collected from human or animal subjects for deferred use, comprising for each of said human or animal subjects the following steps:

- conditioning and preserving successively collected batches of immunocompetent cells, into one or more storage centers, and

- constituting and enhancing from collected batches a personal library of immunocompetent cells, said personal library cumulating a sum of immunity information stored in the walls of the collected immunocompetent cells,

- during successive collections or batches, ~~gathering~~ collecting information characteristic of the status of health and/or the psychological status of said human or animal subject, said status-characterizing information being obtained by processing measurements made on samples ~~of blood and/or fluid and secretions and/or hair collected~~ selected from the group consisting of blood, fluid, secretions, hair and combinations thereof from said human or animal subject, said status-characterizing information ~~gathering~~ collecting being effected before or during the immunocompetent cells collection,

- processing said status-characterizing information for determining the subject's identity data,
- storing, all along said steps, the subject's identify data into a cell management database,
- upon a request for re-use from a cell treatment entity, performing an identification of the personal batches of cells by consulting said cell management database, and receiving from said cell management database said subject's identity data obtained by successive status-characterizing information processing,
- determining parameters of a deferred-use protocol of said batches of immunocompetent cells, by processing said successively collected subject's identity data, and
- providing said cell treatment entity with said identified personal batches of cells and with said deferred-use protocol parameters.

2. (currently amended) The method according to claim 1, ~~characterized in that~~ wherein the status-characterizing information comprise bioelectronic information resulting from processing respective measures of pH, oxidation-reduction potential Rh2 and resistivity ρ of blood previously collected on said human or animal subject (Vincent's bioelectronic method).

3. (currently amended) The method according to claim 1, ~~characterized in that~~ wherein status-characterizing information comprise information obtained by processing sensible crystallization images of blood previously collected on said human or animal subject.

4. (currently amended) The method according to claim 1, ~~characterized in that~~ wherein the status-characterizing information and the immunity information stored in the immunocompetent cells of said human or animal subjects are entered into an expert system used for determining parameters for deferred-use protocols.

5. (currently amended) The method according to claim 4, ~~characterised in that~~ wherein said expert system is arranged for providing an interpretation of said status-characterizing information and said immunity information with respect to a particular gene.

6. (currently amended) The method according to claim 1, ~~implemented~~ further comprising implementing said method in a therapeutic protocol including re-injecting lymphocytes on a human or animal subject, ~~characterised in that~~ wherein the previously collected and preserved immunocompetent cells are submitted to an ex-vivo process before being re-injected.

7. (currently amended) The method according to claim 6, ~~implemented~~ further comprising implementing said method in a therapeutic protocol including re-injecting lymphocytes T with a specific cytotoxic activity after ex-vivo expansion.

8. (currently amended) The method according to claim 6, ~~implemented~~ further comprising implementing said method in a therapy protocol including a step for checking the harmlessness of the lymphocytes before re-injection.

9. (currently amended) The method according to claim 8, ~~implemented~~ further comprising implementing said method in a

therapy protocol including a checking step comprising a test of the oxidative stress of the lymphocytes before re-injection, wherein said lymphocytes are aggressed by free radicals.

10. (currently amended) The method according to claim 9, ~~implemented~~ further comprising implementing said method in a therapy protocol including an oxidative stress test for checking various therapy ways for an ex vivo processing and suitability of said therapy ways with the concerned human or animal subject.

11. (currently amended) The method according to claim 6, ~~implemented~~ further comprising implementing said method in a therapy protocol including an ex vivo processing between lymphocytes and a vaccine before re-injection.

12. (currently amended) The method according to claim 6, ~~implemented~~ further comprising implementing said method in a therapy protocol including an ex vivo processing and an allergic desensitization of the lymphocytes before re-injection.

13. (currently amended) The method according to claim 6, ~~implemented~~ further comprising implementing said method in a therapy protocol including a step for re-injecting lymphocytes by the lymphatic way.

14. (currently amended) The method according to claim 6, ~~implemented~~ further comprising implementing said method in a therapy protocol for transfusing blood from a donor to a receiver, said protocol including substituting lymphocytes from said donor by lymphocytes from said receiver.

15. (currently amended) The method according to claim 1, ~~implemented~~ further comprising implementing said method in a gene therapy protocol.

16. (currently amended) The method according to claim 1, ~~characterized in that it further comprises,~~ further comprising before the step for cryo-preserving a batch of immunocompetent cells, a step of cryogenizing said batch in view of annihilating antibodies present within said batch.

17. (currently amended) The method according to claim 20, ~~characterized in that it further comprises,~~ further comprising before any re-use of a batch of immunocompetent cells previously collected, a step for checking the annihilation of the antibodies within said batch.

18. (currently amended) The method according to claim 1, ~~characterized in that it further comprises,~~ further comprising during conditioning a batch of immunocompetent cells previously collected, a step for immunomagnetically selecting purified lymphocytes or monocytes.

19. (currently amended) A system for managing batches of immunocompetent cells collected from human or animal subjects for their deferred use, said system comprising for each of said human or animal subjects:

- means for conditioning and preserving batches of immunocompetent cells successively collected, into one or more storage centers,

- means for constituting and enhancing from said collected batches a personal library of immunocompetent cells,

said personal library cumulating a sum of immunity information stored in the walls of collected immunocompetent cells,

- means for ~~gathering~~ collecting, during successive collections of batches, information that ~~are~~ is characteristic of said human or animal subject's status of health and/or psychological status, before or during immunocompetent cells collection, said status characterizing information being obtained by processing measurements made on samples ~~of blood and/or fluid and secretions and/or hair collected on~~ selected from the group consisting of blood, fluid, secretions, hair and combinations thereof from said human or animal subject,

- means for processing said status-characterizing information in view of determining said subject's identity data,

- means for storing said subject's identity data successively determined into a cell management database,

- means for performing, upon a request for re-use from a cell treatment entity, an identification of the personal batches of cells to including means for consulting said cell management database,

- means for determining parameters of a deferred-use protocol for said batches of immunocompetent cells from said human or animal subject's personal library, by processing said successively collected subject's identity data, and

- means for providing said cell treatment entity with said identified personal batches of cells and with said determined deferred-use protocol parameters.

20. (currently amended) The system according to claim 19, ~~characterized in that it further comprises~~ further comprising means for getting status-characterizing by processing a blood sample collected on said human or animal subject.

21. (currently amended) The system according to claim 20, ~~characterized in that it further comprises~~ further comprising means for getting bio-electronic information by processing respective measures of the pH, the oxidation-reduction potential and the resistivity of blood previously collected on said human or animal subject.

22. (currently amended) The system according to claim 19, ~~characterized in that it further comprises~~ further comprising means for getting information from a capillary study on elements of said human or animal subject's hair system.

23. (currently amended) The system according to claim 19, ~~characterized in that it further comprises~~ further comprising means for controlling and enhancing an expert system from information characteristic of the status of human or animal subject's and from immunity information stored in said human or animal subject's immunocompetent cells, in view of determining parameters for deferred-use protocols.

24. (currently amended) The system according to claim 23, ~~characterized in that it further comprises~~ further comprising means for providing an interpretation of said human or animal subject's status-characterizing information and said immunity information, with respect of a particular gene.

25. (currently amended) ~~A method for determining parameters of a protocol for a deferred use of immunocompetent cells from a human or animal subject's personal library, said personal library cumulating a sum of immunity information stored in the walls of the immunocompetent cells successively collected and conditioned under the form of batches preserved in one or more storage centers, characterized in that said method comprises:~~

~~- measuring physical and/or biological characteristics done on samples of fluid and/or hair from said human or animal subject before or during the collection of immunocompetent cells,~~
~~- collecting information characteristic of the status of health and/or the physiological status of said human or animal subject's status resulting from said measurements, said status characterizing information being obtained by processing measurements made on samples of blood and/or fluid and secretions and/or collected on said human or animal subject, The method according to claim 1, further comprising:~~

~~- processing said characteristic information in an information system for determining parameters of said deferred-use protocol, and~~

~~- storing said processed information in a cell management data base.~~

26. (canceled without prejudice)